Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology
<p><b>Aims</b></p> Cardiovascular disease is the most common cause of mortality and morbidity in the world, but the pharmaceutical industry's willingness to invest in this field has declined because of the many challenges involved with bringing new cardiovascular drugs t...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2015
|
| _version_ | 1797112672404111360 |
|---|---|
| author | Jackson, N Atar, D Borentain, M Breithardt, G van Eickels, M Endres, M Fraass, U Friede, T Hannachi, H Janmohamed, S Kreuzer, J Landray, M Lautsch, D Le Floch, C Mol, P Naci, H Samani, NJ Svensson, A Thorstensen, C Tijssen, J Vandzhura, V Zalewski, A Kirchhof, P |
| author_facet | Jackson, N Atar, D Borentain, M Breithardt, G van Eickels, M Endres, M Fraass, U Friede, T Hannachi, H Janmohamed, S Kreuzer, J Landray, M Lautsch, D Le Floch, C Mol, P Naci, H Samani, NJ Svensson, A Thorstensen, C Tijssen, J Vandzhura, V Zalewski, A Kirchhof, P |
| author_sort | Jackson, N |
| collection | OXFORD |
| description | <p><b>Aims</b></p>
Cardiovascular disease is the most common cause of mortality and morbidity in the world, but the pharmaceutical industry's willingness to invest in this field has declined because of the many challenges involved with bringing new cardiovascular drugs to market, including late-stage failures, escalating regulatory requirements, bureaucracy of the clinical trial business enterprise, and limited patient access after approval. This contrasts with the remaining burden of cardiovascular disease in Europe and in the world. Thus, clinical cardiovascular research needs to adapt to address the impact of these challenges in order to ensure development of new cardiovascular medicines.
<p><b>Methods and results</b></p>
The present paper is the outcome of a two-day workshop held by the Cardiovascular Round Table of the European Society of Cardiology. We propose strategies to improve development of effective new cardiovascular therapies. These can include (i) the use of biomarkers to describe patients who will benefit from new therapies more precisely, achieving better human target validation; (ii) targeted, mechanism-based approaches to drug development for defined populations; (iii) the use of information technology to simplify data collection and follow-up in clinical trials; (iv) streamlining adverse event collection and reducing monitoring; (v) extended patent protection or limited rapid approval of new agents to motivate investment in early phase development; and (vi) collecting data needed for health technology assessment continuously throughout the drug development process (before and after approval) to minimize delays in patient access. Collaboration across industry, academia, regulators, and payers will be necessary to enact change and to unlock the existing potential for cardiovascular clinical drug development.
<p><b>Conclusions</b></p>
A coordinated effort involving academia, regulators, industry, and payors will help to foster better and more effective conduct of clinical cardiovascular trials, supporting earlier availability of innovative therapies and better management of cardiovascular diseases. |
| first_indexed | 2024-03-07T08:27:10Z |
| format | Journal article |
| id | oxford-uuid:1afa5b3c-048f-4749-9bf7-57b0ec2a6d5d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:27:10Z |
| publishDate | 2015 |
| publisher | Oxford University Press |
| record_format | dspace |
| spelling | oxford-uuid:1afa5b3c-048f-4749-9bf7-57b0ec2a6d5d2024-02-22T17:12:55ZImproving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of CardiologyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:1afa5b3c-048f-4749-9bf7-57b0ec2a6d5dEnglishSymplectic Elements at OxfordOxford University Press2015Jackson, NAtar, DBorentain, MBreithardt, Gvan Eickels, MEndres, MFraass, UFriede, THannachi, HJanmohamed, SKreuzer, JLandray, MLautsch, DLe Floch, CMol, PNaci, HSamani, NJSvensson, AThorstensen, CTijssen, JVandzhura, VZalewski, AKirchhof, P<p><b>Aims</b></p> Cardiovascular disease is the most common cause of mortality and morbidity in the world, but the pharmaceutical industry's willingness to invest in this field has declined because of the many challenges involved with bringing new cardiovascular drugs to market, including late-stage failures, escalating regulatory requirements, bureaucracy of the clinical trial business enterprise, and limited patient access after approval. This contrasts with the remaining burden of cardiovascular disease in Europe and in the world. Thus, clinical cardiovascular research needs to adapt to address the impact of these challenges in order to ensure development of new cardiovascular medicines. <p><b>Methods and results</b></p> The present paper is the outcome of a two-day workshop held by the Cardiovascular Round Table of the European Society of Cardiology. We propose strategies to improve development of effective new cardiovascular therapies. These can include (i) the use of biomarkers to describe patients who will benefit from new therapies more precisely, achieving better human target validation; (ii) targeted, mechanism-based approaches to drug development for defined populations; (iii) the use of information technology to simplify data collection and follow-up in clinical trials; (iv) streamlining adverse event collection and reducing monitoring; (v) extended patent protection or limited rapid approval of new agents to motivate investment in early phase development; and (vi) collecting data needed for health technology assessment continuously throughout the drug development process (before and after approval) to minimize delays in patient access. Collaboration across industry, academia, regulators, and payers will be necessary to enact change and to unlock the existing potential for cardiovascular clinical drug development. <p><b>Conclusions</b></p> A coordinated effort involving academia, regulators, industry, and payors will help to foster better and more effective conduct of clinical cardiovascular trials, supporting earlier availability of innovative therapies and better management of cardiovascular diseases. |
| spellingShingle | Jackson, N Atar, D Borentain, M Breithardt, G van Eickels, M Endres, M Fraass, U Friede, T Hannachi, H Janmohamed, S Kreuzer, J Landray, M Lautsch, D Le Floch, C Mol, P Naci, H Samani, NJ Svensson, A Thorstensen, C Tijssen, J Vandzhura, V Zalewski, A Kirchhof, P Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title_full | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title_fullStr | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title_full_unstemmed | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title_short | Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology |
| title_sort | improving clinical trials for cardiovascular diseases a position paper from the cardiovascular round table of the european society of cardiology |
| work_keys_str_mv | AT jacksonn improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT atard improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT borentainm improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT breithardtg improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT vaneickelsm improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT endresm improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT fraassu improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT friedet improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT hannachih improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT janmohameds improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT kreuzerj improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT landraym improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT lautschd improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT leflochc improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT molp improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT nacih improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT samaninj improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT svenssona improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT thorstensenc improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT tijssenj improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT vandzhurav improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT zalewskia improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology AT kirchhofp improvingclinicaltrialsforcardiovasculardiseasesapositionpaperfromthecardiovascularroundtableoftheeuropeansocietyofcardiology |